Semaglutide is a novel long-acting glucagon-like peptide-1 receptor agonist (GLP-1RA) with a structure similar to natural human glucagon-like peptide-1 (GLP-1), with up to 94% amino acid sequence homology. It is used to control blood sugar in adults with type 2 diabetes.
A novel dual receptor agonist of GIP (gastric inhibitory polypeptide) and GLP-1 (glucagon-like peptide-1)
Mainly used as an antibacterial drug, its antibacterial spectrum is similar to that of penicillin in clinical practice
Release date: February 16, 2025
If you are interested in our products, please submit your email address and we will send you our latest product catalog.